Concerns persist about TNF inhibitor melanoma risk
30th August 2017
By Clare Pain
Australian cancer experts say it is too early to dismiss concerns about melanoma risk in rheumatoid arthritis (RA) patients treated with biologics, despite an apparent “all clear” from European data.
Professor Adele Green and Dr Catherine Olsen (PhD) of the QIMR Berghofer Medical Research Institute in Brisbane have warned that patients taking tumour necrosis factor inhibitors (TNFi) should not be reassured about possible increase in melanoma risk.
In February 2017 a European meta-analysis of data from 130,000
